2022

1. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

   Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

2. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

   Cancer, Vol. 128, Núm. 13, pp. 2441-2448